Cytosorbents' (CTSO) "Buy" Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Cytosorbents (NASDAQ:CTSO - Free Report) in a report released on Wednesday morning,Benzinga reports. The firm currently has a $10.00 price target on the medical research company's stock.

Several other equities research analysts also recently issued reports on CTSO. Wall Street Zen assumed coverage on shares of Cytosorbents in a research report on Wednesday, May 21st. They set a "hold" rating for the company. HC Wainwright restated a "neutral" rating and set a $1.00 price objective on shares of Cytosorbents in a research report on Thursday, May 15th.

Cytosorbents Stock Performance

NASDAQ:CTSO traded up $0.05 during mid-day trading on Wednesday, hitting $1.23. The stock had a trading volume of 187,755 shares, compared to its average volume of 148,918. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $1.61. The stock has a market cap of $77.01 million, a price-to-earnings ratio of -4.39 and a beta of 1.05. The company's 50 day simple moving average is $1.00 and its 200 day simple moving average is $1.01. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.30 and a current ratio of 2.61.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. The firm had revenue of $8.73 million during the quarter, compared to the consensus estimate of $9.01 million. Cytosorbents had a negative net margin of 41.77% and a negative return on equity of 105.04%. On average, equities research analysts forecast that Cytosorbents will post -0.3 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC increased its holdings in shares of Cytosorbents by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock worth $80,000 after purchasing an additional 8,400 shares during the period. Northern Trust Corp increased its holdings in shares of Cytosorbents by 22.3% during the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock worth $83,000 after purchasing an additional 16,701 shares during the period. Millennium Management LLC bought a new position in shares of Cytosorbents during the fourth quarter worth approximately $30,000. Goldman Sachs Group Inc. increased its holdings in shares of Cytosorbents by 149.2% during the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company's stock worth $63,000 after purchasing an additional 37,519 shares during the period. Finally, Key Client Fiduciary Advisors LLC increased its holdings in shares of Cytosorbents by 127.0% during the first quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company's stock worth $78,000 after purchasing an additional 43,900 shares during the period. 32.87% of the stock is owned by institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.